Filing Flows

Filing Flows › 8-K events › Bio Essence

Bio Essence: departure or appointment of directors and officers

Form 8-K filed Oct 23, 2026 · items 5.02, 5.03

What the filing says

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers On October 19, 2026, a majority of shareholders of Bio Essence Corp., a California corporation (“Company”) elected by way of written consent Thea Zhang and Geoff Fellows as a

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Item 5.03: +0.1% next session across 5,869. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Bio Essence at a glance

Latest quarterQ2 2026
Revenue$795K
Revenue Y/Y+207%
Operating margin35.1%
IndustryPharmaceutical Preparations

Bio Essence, Q2 2026: revenue $795K (+207% year over year), operating margin 35.1%. The chart follows the revenue to costs, profit and cash.

Bio Essence: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent ceo changes

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.